Inventiva's Full H1 2026 Report Flags Going Concern, Cash Runway to Q2 2027, and 31.6% Potential Dilution
IVA is trading near its 52-week low of $3.105 (4.5% above the low) on elevated volume (2.5× avg).
Summary
Inventiva's full H1 2026 report confirms a going-concern warning: €233.9M in cash and deposits funds operations only to Q2 2027, with 31.6% potential dilution from outstanding instruments. The company's future hinges on the Q4 2026 NATiV3 topline readout.
Key Events · Earnings and Guidance · IVA
-
Going Concern Warning Confirmed
Cash and cash equivalents of €166.1M plus €67.8M in short-term deposits are insufficient to cover operating needs for the next 12 months. The company states a material uncertainty exists that may cast significant doubt on its ability to continue as a going concern.
-
Cash Runway to Q2 2027
Current resources fund operations until end of Q2 2027. Extending to start of Q1 2028 requires full exercise of T3 Warrants (up to €116M) and Tranche C debt (up to €55M), both contingent on positive NATiV3 topline data expected Q4 2026.
-
31.6% Potential Dilution
Full exercise of all dilutive instruments — employee warrants/options, New EIB Warrants, and 61.7M pre-funded warrants — would dilute shareholders by 31.6%. New EIB Warrants alone represent 6.64% of shares outstanding.
-
NATiV3 Topline Readout Q4 2026
Last patient completed final 72-week visit on September 2, 2026. Topline results from the Phase 3 trial of lanifibranor in MASH are expected in Q4 2026, with NDA filing targeted for H1 2027 if positive.
Analysis · IVA · Life Sciences
The complete H1 2026 interim report from Inventiva confirms that current cash of €166.1M plus €67.8M in short-term deposits will not cover operating needs for the next 12 months. Explicit going-concern language highlights a material uncertainty that may cast significant doubt on the company's ability to continue. The runway extends only to end of Q2 2027, and reaching Q1 2028 requires full exercise of T3 Warrants (up to €116M) and Tranche C debt (up to €55M) — both contingent on positive NATiV3 topline data expected Q4 2026. The filing also quantifies dilution risk: full exercise of all dilutive instruments would dilute shareholders by 31.6%, with the New EIB Warrants alone representing 6.64% of shares outstanding. Against this backdrop, the company granted 3M stock options to Chairman Mark Pruzanski and 1.067M to CPO Pamela Herbster. The stock trades near its 52-week low of $3.105, reflecting the market's concern about the binary NATiV3 readout and financing overhang.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVA was trading at $3.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $765.4M. The 52-week trading range was $3.11 to $7.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.